羧化全酶合成酶缺陷病的临床诊治及基因突变分析

王彤, 叶军, 韩连书, 邱文娟, 张惠文, 张雅芬, 高晓岚, 王瑜, 顾学范

中国当代儿科杂志 ›› 2009, Vol. 11 ›› Issue (08) : 609-612.

PDF(1187 KB)
PDF(1187 KB)
中国当代儿科杂志 ›› 2009, Vol. 11 ›› Issue (08) : 609-612.
论著·临床研究

羧化全酶合成酶缺陷病的临床诊治及基因突变分析

  • 王彤,叶军,韩连书,邱文娟,张惠文,张雅芬,高晓岚,王瑜,顾学范
作者信息 +

Diagnosis,treatment and gene mutation analysis in children with holocarboxylase synthetas deficiency

  • WANG Tong, YE Jun, HAN Lian-Shu, QIU Wen-Juan, ZHANG Hui-Wen, ZHANG Ya-Fen, GAO Xiao-Lan, WANG Yu, GU Xue-Fan.
Author information +
文章历史 +

摘要

目的:报道羧化全酶合成酶(holocarboxylase synthetas, HCS)缺陷病的诊治及随访情况,了解该疾病的基因突变谱。方法:①采用质谱分析及生物素酶活性测定进行HCS缺陷病的诊断。②采用聚合酶链反应-直接测序法进行HCS基因突变分析。③11例HCS缺陷病患儿中10例接受了生物素的治疗(10~40 mg/d),对其疗效进行随访观察。结果:①11例患儿均有不同程度精神萎靡、嗜睡及代谢性酸中毒,10例患儿有皮肤损害。质谱分析血3-羟基异戊酰肉碱,尿3-甲基巴豆酰甘氨酸、甲基枸橼酸等增高。生物素酶活性与正常对照者生物素酶活性的比值>30%。②发现4种突变:c.1522C>T(R508W),c.1088T>A(V363D),c.126G>T(E42D),c.1994G>C(R665P)(新变异)。实变频率分别为50%,29%,7%,14%。③10例接受生物素治疗的患儿,1~2周后临床症状消失,2~6月后异常代谢产物多下降至正常。结论:HCS缺陷病以神经系统及皮肤损害、代谢性酸中毒为特征。质谱分析、生物素酶活性测定、基因突变分析有助于明确诊断,口服生物素疗效显著。突变R508W和V363D可能是中国患儿的常见突变。[中国当代儿科杂志,2009,11(8):609-612]

Abstract

OBJECTIVE: To report the clinical diagnosis, treatment and follow-up of children with holocarboxylase synthetas(HCS) deficiency and explore the gene mutation spectrum of the disease. METHODS: Eleven children with HCS deficiency were enrolled. Mass spectrometry analysis and biotinidase activity determination were used for diagnosis of HCS deficiency. HCS gene mutations were analyzed by PCR directed sequencing methods. Ten patients received oral biotin treatment (10-40 mg/d). Clinical effects of biotin treatment were observed. RESULTS: All 11 cases developed apathetic, lethargy and metabolic acidosis at different degrees, and 10 cases presented with skin lesions. The average blood 3-hydroxyisovaleryl-carnitine concentrations and urinary 3-methylcrontonylglycine and methylcitrate concentrations increased significantly. The biotinidase activity increased, being higher over 30% of the normal reference value. Four mutations in HCS gene were identified, and they were c.1522C>T (R508W), c.1088T>A (V363D), c.126G>T (E42D) and c.1994G>C (R665P) (a new variant) and the frequency was 50%, 29%, 7% and 14% respectively. The symptoms disappeared in 10 cases 1-2 weeks after biotin treatment, and blood and urinary abnormal metabolites were gradually reduced to normal 2-6 months after treatment. CONCLUSIONS: HCS deficiency is characterized by nervous system damage, skin lesions and metabolic acidosis. Mass spectrometry analysis, biotinidase activity determination and gene mutation analysis may be helpful in the definite diagnosis of this disorder. The effect of early biotin treatment is satisfactory. The mutations R508W and V363D might be hot-spots in Chinese children with HCS deficiency.[Chin J Contemp Pediatr, 2009, 11 (8):609-612]

关键词

羧化全酶合成酶 / 生物素酶 / 串联质谱 / 气相色谱质谱 / 基因 / 儿童

Key words

Holocarboxylase-synthetas / Biotinidase / Tandem mass spectrometry / Gas chromatography/ mass spectrometry / Gene / Child

引用本文

导出引用
王彤, 叶军, 韩连书, 邱文娟, 张惠文, 张雅芬, 高晓岚, 王瑜, 顾学范. 羧化全酶合成酶缺陷病的临床诊治及基因突变分析[J]. 中国当代儿科杂志. 2009, 11(08): 609-612
WANG Tong, YE Jun, HAN Lian-Shu, QIU Wen-Juan, ZHANG Hui-Wen, ZHANG Ya-Fen, GAO Xiao-Lan, WANG Yu, GU Xue-Fan. Diagnosis,treatment and gene mutation analysis in children with holocarboxylase synthetas deficiency[J]. Chinese Journal of Contemporary Pediatrics. 2009, 11(08): 609-612
中图分类号: R596.1   

参考文献

[1]张春花. 先天性代谢异常的预防诊断与治疗[J].中国当代儿科杂志,2005,7(5):477-480.
[2]谢利娟,朱建幸,朱晓东,李华军,韩连书,顾学范. 经高危筛查发现的遗传性代谢病15例分析[J].中国当代儿科杂志,2008,10(1):31-34.
[3]Han LS, Ye J, Qiu WJ, Gao XL, Wang Y, Gu XF. Selective screening for inborn errors of metabolism on clinical patients using tandem mass spectrometry in China: a fouryear report[J].J Inherit Metab Dis, 2007, 30(4):507-514.
[4]韩连书,高晓岚,叶军,邱文娟,顾学范. 串联质谱分析干血滤纸片酰基肉碱方法的建立[J].中华检验医学杂志, 2005, 28(1):88-91.
[5]宋金青,杨艳玲,孙芳,张月华,包新华,钱宁,等.气相色谱质谱联用分析在有机酸尿症筛查与诊断中的应用[J].中国医刊, 2006, 41(2):38-40.
[6]宋元宗,方素珍,封志纯,王自能. 尿素酶预处理-气相色谱-质谱法在多种羧化酶缺陷病诊断治疗中的应用[J].中国当代儿科杂志,2004,6(2):128-130.
[7]Suzuki Y, Yang X, Aoki Y, Kure S, Matsubara Y. Mutations in the holocarboxylase synthetase gene HLCS [J].Hum mutat, 2005, 26(4):285-290.
[8]Wolf B. Disorders of biotin metabolism[M]. //Scriver CR, Beaudet AL, Sly WS, Valle D. The metabolic and molecular basis of inherited disease.8th ed.New York:McGraw Hill, 2001, 3935-3962.
[9]邹丽萍,王旭. 疑难病研究—生物素酶缺乏症[J].中国当代儿科杂志,2005,7(5) :435-438.
[10]Morrone A, Malvagia S, Donati MA, Funghini S, Ciani F, Pela I, et al. Clinical findings and biochemical and molecular analysis of four patients with holocarboxylase synthetase deficiency[J]. Am J Med Genet, 2002, 111(1):10-18.
[11]叶军,韩连书,邱文娟,张惠文,高晓岚,王瑜,等. 联合质谱技术在多种羧化酶缺陷病诊治中的应用[J].中国实用儿科杂志, 2008, 23(8):582-585.
[12]Santer R, Muhle H, Suormala T, Baumgartner ER, Duran M, Yang X, et al. Partial response to biotin therapy in a patient with holocarboxylase synthetase deficiency: clinical, biochemical, and molecular genetic aspects[J]. Mol Genet Metab, 2003, 79(3):160-166.
[13]Dupuis L, Campeau E, Leclerc D, Gravel RA. Mechanism of biotin responsiveness in biotin-responsive multiple carboxylase deficiency[J]. Mol Genet Metab, 1999, 66(2):80-90.


PDF(1187 KB)

Accesses

Citation

Detail

段落导航
相关文章

/